Multiple Sclerosis Therapeutics, Third Edition

Overview

Since the publication of the previous edition of this volume, there has been substantial progress in a number of areas of multiple sclerosis (MS) research. Although immunosuppressive treatments continue to be developed and refined, more targeted immunomodulatory therapies are surfacing as we learn more about how the immune system works in health and disease.

Multiple Sclerosis Therapeutics, Third Edition provides a comprehensive review of clinical trial methodology and ...

See more details below
Other sellers (Hardcover)
  • All (8) from $79.95   
  • New (5) from $209.99   
  • Used (3) from $79.95   
Sending request ...

Overview

Since the publication of the previous edition of this volume, there has been substantial progress in a number of areas of multiple sclerosis (MS) research. Although immunosuppressive treatments continue to be developed and refined, more targeted immunomodulatory therapies are surfacing as we learn more about how the immune system works in health and disease.

Multiple Sclerosis Therapeutics, Third Edition provides a comprehensive review of clinical trial methodology and therapeutic modalities in MS. This edition reflects current understanding of the pathophysiology of the disease and includes popular and emerging treatments.

Topics include:

  • Biomarkers in MS
  • Pharmacogenomics
  • Emerging therapeutic modalities such as natalizumab, T-cell-based and B-cell-based therapies, cytokine/chemokine-based therapies, statins, and 4-aminopyridine
  • Neuroprotection
  • The use of OCT and MRI to guide disease therapy

Within the next several years, we will begin to discover the utility and the limitations of stem cells in the treatment of MS. It is likely that the next edition of this text will include clinical trial data that evaluate early attempts at nervous system regeneration in MS. Until that time occurs, this volume remains an essential resource for neurologists and anyone involved in the treatment of MS.

Read More Show Less

Product Details

  • ISBN-13: 9781841845258
  • Publisher: Taylor & Francis
  • Publication date: 12/1/2006
  • Edition number: 3
  • Pages: 928
  • Product dimensions: 7.80 (w) x 9.90 (h) x 2.10 (d)

Meet the Author

Jeffrey Cohen

JEFFREY A. COHEN is a principal of Chicago Partners, a finance, economics, valuation, and accounting consulting firm that specializes in the application of those disciplines to legal and regulatory matters. Cohen is also Director of the Intellectual Property Practice at Chicago Partners. He has been a consultant to Fortune 500 companies, government, and the nation's premier law firms for more than sixteen years. Cohen earned his BA and MBA from the University of Chicago.

Read More Show Less

Table of Contents

1. Aspects of multiple sclerosis that relate to trial design and clinical management. 2. Biological concepts of multiple sclerosis pathogenesis and relationship to treatment. 3. The multiple sclerosis disease process as characterized by magnetic resonance imaging. 4. Measures of neurological impairment and disability in multiple sclerosis. 5. Assessment of neuropsychological function in multiple sclerosis. 6. Health-related quality of life assessment in multiple sclerosis. 7. Measures of gadolinium enhancement, T1 black holes and T2-hyperintense magnetic resonance imaging in multiple sclerosis. 8. Measures of magnetization transfer in multiple sclerosis. 9. Measurement of central nervous system atrophy in multiple sclerosis. 10. Axonal pathology in patients with multiple sclerosis: evidence from in vivo proton magnetic resonance spectroscopy. 11. Functional imaging in multiple sclerosis. 12. Magnetic resonance imaging of pathway-specific structure and function in multiple sclerosis. 13. Optical coherence tomography to monitor neuronal integrity in multiple sclerosis. 14. Biomarkers in multiple sclerosis. 15. The process of drug development and approval in
the United States, the European Union and Canada. 16. Selection and interpretation of end-points in multiple sclerosis clinical trials. 17. Clinical trial logistics. 18. The challenge of long-term studies in multiple sclerosis: use of pooled data, historical controls and observational studies to determine efficacy. 19. Alternative designs for multiple sclerosis clinical trials. 20. Ethical considerations in multiple sclerosis clinical trials. 21. Pharmacogenetics and pharmacogenomics in multiple sclerosis. 22. Interferons in relapsing.remitting multiple sclerosis. 23. Interferons in secondary progressive multiple sclerosis. 24. Neutralizing antibodies directed against interferon A. 25. Glatiramer acetate as therapy for multiple sclerosis. 26. Use of mitoxantrone to treat multiple sclerosis. 27. Use of cyclophosphamide and other immunosuppressants
to treat multiple sclerosis. 28. Natalizumab in multiple sclerosis. 29. High-dose methylpredisolone in the treatment of multiple sclerosis. 30. Intravenous immunoglobulin in multiple sclerosis. 31. Therapeutic plasma exchange for multiple sclerosis. 32. Statins in multiple sclerosis. 33. Stem cell transplantation for multiple sclerosis. 34. T cell-based therapies in multiple sclerosis. 35. B cell-based therapies for multiple sclerosis and related diseases. 36. Chemokines and central nervous system inflammation: relevance to multiple sclerosis. 37. Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis. 38. Neuroprotection in multiple sclerosis. 39. Combination therapy in multiple sclerosis. 40. Fampridine in multiple sclerosis. 41. Complementary and alternative treatments in multiple sclerosis.
42. Disease-modifying therapy for multiple sclerosis in clinical practice. 43. Treatment for patients with primary progressive multiple sclerosis. 44. Use of magnetic resonance imaging in clinical management of multiple sclerosis. 45. Fatigue in multiple sclerosis.
46. Management of spasticity in multiple sclerosis. 47. Management of bladder and sexual dysfunction in multiple sclerosis. 48. Depression in multiple sclerosis. 49. Treatment of pain, paresthesias and paroxysmal disorders in multiple sclerosis. 50. Rehabilitation in multiple sclerosis patients.

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)